Skip to content

Precise medical study of TSH inhibitory therapy based on etiological classification of thyroid carcinoma

Precise medical study of TSH inhibitory therapy based on etiological classification of thyroid carcinoma

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024212
Enrollment
Unknown
Registered
2019-06-30
Start date
2019-07-01
Completion date
Unknown
Last updated
2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

differentiated thyroid cancer

Interventions

app-using group:base on apps
the traditional medical model group:visit the outpatient department

Sponsors

Endocrinology Department, Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged 18 to 70 years; 2. met the diagnostic criteria of differentiated thyroid cancer (based on operation and pathology), and the results of BRAF gene test were found; 3. the patients who had completed total thyroidectomy, subtotal thyroidectomy and partial thyroidectomy did not exceed 3 months after operation; 4. the examination of bone metabolism and echocardiography was improved before operation; 5. clear consciousness and understanding ability; 6. volunteered to participate in this study.

Exclusion criteria

Exclusion criteria: 1. metastasis of other tissues and organs; 2. complicated with other malignant tumors; 3. complicated with other diseases: nephropathy, liver disease, malnutrition, hyperparathyropathy, hyperthyroidism, pituitary dysfunction, diabetes, coronary heart disease, hypertension, rheumatoid arthritis, ankylosing spondylitis, Paget's osteopathy, non-traumatic fracture, bone deformity, etc. 4. there is a long history of use of steroids, antiepileptic drugs, diuretics and fluoride. 5. those who are unable to move, or can not communicate normally.

Design outcomes

Primary

MeasureTime frame
F-T4;TSH;Tg;ATG;ATPO;GLU;Ca;P;Mg;LDL-C;TG;PTH;BMD;ALP;

Secondary

MeasureTime frame
CK;CK-MB;

Countries

China

Contacts

Public ContactHao Yabin

Endocrinology Department, Beijing Friendship Hospital, Capital Medical University

hyaya@msn.com+86 18511878214

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026